主权项 |
1. A method for treating inner ear conditions associated with or characterized by aberrant glutamatergic signaling in the inner ear, comprising administration of a pharmaceutical composition comprising an amount of a modulator of a Group I mGluR sufficient to treat the conditions, wherein the composition is a controlled release gel formulation administered on or near the round window membrane of the inner ear, wherein the modulator of a Group I mGluR is 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC), and wherein the inner ear condition is selected from excitotoxicity, presbycusis, tinnitus, and noise-induced hearing loss. |